These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 8052271)
1. The role of the plasma from platelet concentrates in transfusion reactions. Heddle NM; Klama L; Singer J; Richards C; Fedak P; Walker I; Kelton JG N Engl J Med; 1994 Sep; 331(10):625-8. PubMed ID: 8052271 [TBL] [Abstract][Full Text] [Related]
2. Generation of IL-8 and TNF-alpha in platelet concentrates during storage. Shaiegan M; Pourfatollah AA; Namiri M; Babaee G Arch Iran Med; 2006 Jan; 9(1):61-4. PubMed ID: 16649381 [TBL] [Abstract][Full Text] [Related]
4. Autologous platelet transfusion in patients receiving high-dose chemotherapy and circulating progenitor cell transplantation for stage II/III breast cancer. Pedrazzoli P; Perotti C; Noris P; Da Prada GA; Zibera C; Battaglia M; Gibelli N; Preti P; Pavesi L; Torretta L; Balduini CL; Salvaneschi L; Robustelli della Cuna G Haematologica; 1998 Aug; 83(8):718-23. PubMed ID: 9793256 [TBL] [Abstract][Full Text] [Related]
5. An association of soluble CD40 ligand (CD154) with adverse reactions to platelet transfusions. Blumberg N; Gettings KF; Turner C; Heal JM; Phipps RP Transfusion; 2006 Oct; 46(10):1813-21. PubMed ID: 17002639 [TBL] [Abstract][Full Text] [Related]
6. Extracellular accumulation of bioactive substances during preparation and storage of various platelet concentrates. Edvardsen L; Taaning E; Dreier B; Christensen LD; Mynster T; Nielsen HJ Am J Hematol; 2001 Jul; 67(3):157-62. PubMed ID: 11391711 [TBL] [Abstract][Full Text] [Related]
7. Reduction in adverse reactions to platelets by the removal of plasma supernatant and resuspension in a new additive solution (M-sol). Azuma H; Hirayama J; Akino M; Miura R; Kiyama Y; Imai K; Kasai M; Koizumi K; Kakinoki Y; Makiguchi Y; Kubo K; Atsuta Y; Fujihara M; Homma C; Yamamoto S; Kato T; Ikeda H Transfusion; 2009 Feb; 49(2):214-8. PubMed ID: 18798806 [TBL] [Abstract][Full Text] [Related]
8. Prevention of cytokine accumulation in platelets obtained with the COBE spectra apheresis system. Palmer DS; Aye MT; Dumont L; Dumont D; McCombie N; Giulivi A; Rutherford B; Trudel E; Hashemi-Tavoularis S Vox Sang; 1998; 75(2):115-23. PubMed ID: 9784664 [TBL] [Abstract][Full Text] [Related]
9. A prospective observational study of the effect of platelet transfusions on levels of platelet-derived cytokines, chemokines and interleukins in acute leukaemia patients with severe chemotherapy-induced cytopenia. Apelseth TO; Hervig T; Wentzel-Larsen T; Petersen K; Reikvam H; Bruserud Ø Eur Cytokine Netw; 2011 Mar; 22(1):52-62. PubMed ID: 21388914 [TBL] [Abstract][Full Text] [Related]
10. [Cytokines and chemokines as inducers of nonhemolytic transfusion reactions after thrombocyte transfusion]. Klüter H; Wilhelm D; Bubel S; Fiebelkorn A; Kirchner H Beitr Infusionsther Transfusionsmed; 1997; 34():100-4. PubMed ID: 9417331 [TBL] [Abstract][Full Text] [Related]
11. An approach to prevent the severe adverse events associated with transfusion of FDA-approved blood products. Valeri CR; Ragno G Transfus Apher Sci; 2010 Jun; 42(3):223-33. PubMed ID: 20392670 [TBL] [Abstract][Full Text] [Related]
12. Current status of leukocyte and platelet administration in cancer therapy. Walker EM; Cannon A; Mitchum EN Ann Clin Lab Sci; 1983; 13(6):453-73. PubMed ID: 6197928 [TBL] [Abstract][Full Text] [Related]